• Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 2,133.14%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.22
▼ -0.01 (-4.28%)

This chart shows the closing price for NCNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NuCana Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NCNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NCNA

Analyst Price Target is $5.00
▲ +2,133.14% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for NuCana in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 2,133.14% upside from the last price of $0.22.

This chart shows the closing price for NCNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in NuCana. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/18/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/16/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$4.00Low
11/21/2023OppenheimerReiterated RatingOutperform ➝ Outperform$4.00Low
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$6.00Low
8/18/2023OppenheimerReiterated RatingOutperform ➝ Outperform$4.00Low
11/28/2022CitigroupLower Target$5.00 ➝ $2.00Low
9/22/2022Jefferies Financial GroupLower TargetBuy$21.00 ➝ $3.00Low
4/13/2022Truist FinancialLower Target$22.00 ➝ $6.00High
3/3/2022CowenDowngradeOutperform ➝ Market PerformHigh
11/24/2021HC WainwrightLower TargetBuy$10.00 ➝ $9.00High
3/30/2021William BlairReiterated RatingBuyMedium
1/19/2021HC WainwrightReiterated RatingBuy$10.00Low
12/1/2020HC WainwrightLower TargetBuy$15.00 ➝ $10.00High
11/24/2020HC WainwrightLower TargetBuy$17.00 ➝ $15.00High
10/22/2020Truist FinancialInitiated CoverageBuy$22.00High
9/21/2020OppenheimerReiterated RatingBuy$21.00Medium
8/21/2020Piper SandlerBoost TargetOverweight$15.00 ➝ $17.00High
8/21/2020HC WainwrightBoost TargetBuy$16.00 ➝ $17.00High
8/21/2020OppenheimerReiterated RatingBuy$21.00High
7/29/2020CowenReiterated RatingMarket Perform ➝ AverageLow
7/29/2020Piper SandlerReiterated RatingOverweight$15.00Low
7/23/2020OppenheimerInitiated CoverageOutperform$20.00High
5/19/2020HC WainwrightReiterated RatingBuy$16.00High
5/6/2020HC WainwrightReiterated RatingBuyLow
3/11/2020HC WainwrightLower TargetBuy$17.00 ➝ $16.00High
11/15/2019Piper Sandler CompaniesLower TargetOverweight$25.00 ➝ $15.00Low
11/15/2019HC WainwrightReiterated RatingBuy$20.00 ➝ $17.00High
10/29/2019HC WainwrightReiterated RatingBuy$20.00High
10/25/2019CowenReiterated RatingBuyLow
9/5/2019William BlairReiterated RatingBuyHigh
8/23/2019Piper Sandler CompaniesReiterated RatingOverweight$35.00 ➝ $25.00Low
8/21/2019CitigroupSet TargetBuy$25.00Low
8/20/2019Piper Sandler CompaniesSet TargetBuy$35.00Low
8/19/2019HC WainwrightInitiated CoverageBuy$20.00High
5/16/2019William BlairReiterated RatingOutperformLow
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
10/17/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NuCana logo
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More

Today's Range

Now: $0.22
Low: $0.22
High: $0.24

50 Day Range

MA: $0.31
Low: $0.22
High: $0.42

52 Week Range

Now: $0.22
Low: $0.22
High: $0.96

Volume

262,460 shs

Average Volume

568,726 shs

Market Capitalization

$11.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of NuCana?

The following sell-side analysts have issued reports on NuCana in the last year: Oppenheimer Holdings Inc., and Truist Financial Co..
View the latest analyst ratings for NCNA.

What is the current price target for NuCana?

2 Wall Street analysts have set twelve-month price targets for NuCana in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 2,133.1%. Truist Financial Co. has the highest price target set, predicting NCNA will reach $6.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $4.00 for NuCana in the next year.
View the latest price targets for NCNA.

What is the current consensus analyst rating for NuCana?

NuCana currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NCNA will outperform the market and that investors should add to their positions of NuCana.
View the latest ratings for NCNA.

What other companies compete with NuCana?

How do I contact NuCana's investor relations team?

NuCana's physical mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company's listed phone number is 441313571111 and its investor relations email address is [email protected]. The official website for NuCana is www.nucana.com. Learn More about contacing NuCana investor relations.